Gilead Sciences’ (NASDAQ:GILD) executives answered several questions about its pending acquisition of Kite Pharma (NASDAQ:KITE) last week at the Citi biotech conference. However, that discussion didn’t include the company’s CEO, John Milligan.
Gilead Sciences’ (NASDAQ:GILD) executives answered several questions about its pending acquisition of Kite Pharma (NASDAQ:KITE) last week at the Citi biotech conference. However, that discussion didn’t include the company’s CEO, John Milligan.
